Lumbar Disc Herniation
Conditions
Interventions
Yaotaitongning Capsule Group:The oral administration of Yaotuaining Capsules, with a specification of 0.3g per capsule, is recommended at a dosage of 6 capsules per dose, three times daily, for a trea
Celecoxib Capsule Group:Celecoxib capsules are taken orally, with a specification of 0.1g per capsule, once or twice daily. The total dosage should be administered according to the instructions and cl
Waibotong Capsule Group:Liaobaitong Capsules, taken orally, with each capsule weighing 0.42g. The recommended dosage is 3 capsules per dose, three times daily, preferably taken after meals, for a 12-w
Sponsors
Affiliated Hospital of Changchun University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Include patients with lumbar disc herniation aged 18-75 years, regardless of gender; patients should meet the modern medical diagnostic criteria for lumbar disc herniation, presenting with typical lumbosacral pain and/or sciatica, with MRI or CT showing disc herniation at the corresponding segment, and imaging findings consistent with clinical symptoms and signs; disease duration of at least 3 months, no prior or refusal of surgical treatment, and eligible for conservative treatment; baseline resting VAS score of no less than 4 points; conscious, good comprehension ability, able to complete questionnaires and follow-up as required; voluntarily participating in this study and signing a written informed consent form.
Exclusion criteria
Exclusion criteria: Exclude patients with severe heart, liver, kidney, hematopoietic system diseases, or malignant tumors; those with a history of allergy to nonsteroidal anti-inflammatory drugs, components of Lutai Tongning capsules, or components of Yaobitong capsules; those who have undergone lumbar surgery or vertebral interventional treatment within the past 3 months; those with severe mental disorders or significantly impaired cognitive function who are unable to cooperate with treatment and assessment; pregnant or breastfeeding women, or those planning pregnancy in the near future; and those currently participating in other clinical trials and still in the follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Visual Analog Scale (VAS) score for rest pain from baseline.;Significant pain relief rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Oswestry Disability Index change value;Japanese Orthopedic Association Lumbar Functional Score Change Value;Health Status Survey Brief Form Total Score Change Value;The change value of the angle in the straight leg raising test;Adverse Event Incidence Rate;Laboratory Safety Metrics Changes;Quality-Adjusted Life Year and Incremental Cost-Utility Ratio; | — |
Countries
China
Contacts
Public ContactLuo Zongjian
Affiliated Hospital of Changchun University of Chinese Medicine
Outcome results
None listed